Novan, Inc.
21
0
0
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 21 trials
100.0%
+13.5% vs industry average
29%
6 trials in Phase 3/4
43%
9 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
P3 Study in Acne Comparing Once Daily SB204 and Vehicle
Role: lead
P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne
Role: lead
P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris
Role: lead
P3 Long Term Safety Study of Once Daily SB204 in Acne
Role: lead
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
Role: lead
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Role: lead
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
Role: lead
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
Role: lead
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
Role: lead
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
Role: lead
A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers
Role: lead
SB208 for the Treatment of Tinea Pedis
Role: lead
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
Role: lead
A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne
Role: lead
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
Role: lead
A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel
Role: lead
Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris
Role: lead
Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris
Role: lead
A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis
Role: lead
A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis
Role: lead